Հակաֆոսֆոլիպիդային համախտանիշի նորարարությունները. կլինիկական մարտահրավերները և գիտական առաջընթացը

<jats:p>Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistent antiphospholipid antibodies (aPL). Classification of APS, for identifying homogeneous research cohorts, is currently based on the Sapporo criteria published in 1999 and revised in 2006. The revised Sapporo criteria for APS require clinical manifestations (thrombosis or obstetrical pathology) and positive laboratory tests (lupus anticoagulant, IgG/IgM anticardiolipin antibodies, and/or IgG/IgM anti–β2-glycoprotein I antibodies) with at least 2 aPL tests performed at least 12 weeks apart. The new diagnostic criteria for APS have a number of advantages, including: high specificity, accuracy, and a weighted assessment of risk factors for arterial and venous thrombosis. The expanded clinical criteria allow for the creation of a homogeneous group of patients with a high probability of having APS. According to the new laboratory criteria, antibodies are differentiated by moderate (40 79 units) and high (&gt;80 units) titers, as well as IgG and IgM classes of antibodies, giving preference to IgG antibodies, which allows for a more accurate diagnosis of APS. The disease is diagnosed if there are at least 3 points according to clinical criteria and 3 points according to laboratory criteria.</jats:p>